The Verdict
Scott Minerd has returned -0.1% vs S&P -3.1% over matched windows (13% win rate across 19 picks).
The Report Card
Every pick at a glance. Green = beat S&P. Red = didn't.
Scott Minerd's Stock Recommendations, Graded
- DNTH · BUY · Mar 15, 2026
Dianthus Therapeutics
Return -0.3% vs S&P -3.1%
- S · BUY · Mar 14, 2026
SentinelOne
Return -0.8% vs S&P -3.1%
- GRAL · BUY · Mar 14, 2026
GRAIL Inc
Return +2.4% vs S&P -3.1%
- FWONK · BUY · Mar 13, 2026
Liberty Formula One
Return -2.7% vs S&P -2.1%
Scott Minerd's Best and Worst Stock Picks
Best: RLAY (+144.1%) · Worst: MNDY (-52.3%).
Scott Minerd's Full Track Record
| Action | Ticker | Date | Headline | Return | vs S&P |
|---|
| BUY | DNTH | | DNTH: Dianthus Therapeutics — BUY Mar 2026Guggenheim reiterates buy rating for Dianthus Therapeutics (DNTH) | -0.3% | +2.8% |
| BUY | S | | S: SentinelOne — BUY Mar 2026Guggenheim Reaffirms Their Buy Rating on SentinelOne (S) | -0.8% | +2.2% |
| BUY | GRAL | | GRAL: GRAIL Inc — BUY Mar 2026Guggenheim Sticks to Their Buy Rating for GRAIL Inc (GRAL) | +2.4% | +5.4% |
| BUY | FWONK | | FWONK: Liberty Formula One — BUY Mar 2026Guggenheim reiterates Liberty Formula One stock Buy on race cancellations | -2.7% | -0.6% |
| BUY | ORKA | | ORKA: Oruka Therapeutics — BUY Mar 2026Oruka Therapeutics (NASDAQ:ORKA) Earns "Buy" Rating from Guggenheim | -2.7% | -0.7% |
| BUY | SGMT | | SGMT: Sagimet Biosciences — BUY Mar 2026Guggenheim Maintains Sagimet Biosciences(SGMT.US) With Buy Rating | -7.5% | -5.4% |
| BUY | RLAY | | RLAY: Relay Therapeutics — BUY Mar 2026Guggenheim Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price | -4.3% | -2.3% |
| BUY | ABBV | | ABBV: AbbVie — BUY Mar 2026Guggenheim Reiterates Buy Rating on Abbvie (ABBV) | -9.0% | -6.4% |
| BUY | VYGR | | VYGR: Voyager Therapeutics — BUY Mar 2026Guggenheim Remains a Buy on Voyager Therapeutics (VYGR) | -20.9% | -18.3% |
| BUY | ONC | | ONC: BeOne Medicines — BUY Feb 2026Guggenheim Forecasts Strong Price Appreciation for BeOne Medicines | -13.2% | -7.7% |
| BUY | RYTM | | RYTM: Rhythm Pharmaceuticals — BUY Feb 2026Guggenheim Issues Positive Forecast for Rhythm Pharmaceuticals | -5.7% | -0.2% |
| BUY | LOW | | LOW: Lowe's Companies — BUY Feb 2026Guggenheim Forecasts Strong Price Appreciation for Lowe's Companies | -15.0% | -9.1% |
| BUY | ATAI | | ATAI: AtaiBeckley — BUY Jan 2026Guggenheim Initiates Buy Rating for AtaiBeckley | -7.2% | -0.9% |
| BUY | ORCL | | ORCL: Oracle Corporation — BUY Dec 2025Oracle stock remains Guggenheim's Best Idea | -24.7% | -18.8% |
| BUY | MNDY | | MNDY: Monday.com — BUY Dec 2025Monday.com stock initiated with Buy rating at Guggenheim | -52.3% | -47.0% |
| BUY | CYBN | | CYBN: Cybin Inc. — BUY Dec 2025Guggenheim raises Cybin stock price target | +37.8% | +37.0% |
| SELL | GTLB | | GTLB: GitLab — SELL Sep 2025Guggenheim Asserts GitLab's Inc. 'Buy' Rating | ✓ Correct | +54.0% |
| BUY | SMMT | | SMMT: Summit Therapeutics — BUY Sep 2025Guggenheim Initiates Summit Therapeutics With a Buy Rating | -17.6% | -17.4% |
| BUY | RLAY | | RLAY: Relay Therapeutics — BUY Sep 2025Guggenheim Gives Buy Rating to Relay Therapeutics | +144.1% | +144.1% |
FAQ
Is Scott Minerd good at picking stocks?
Scott Minerd has 19 scored picks with 13% win rate and +3.1% vs S&P.
What stocks does Scott Minerd recommend?
RLAY, SMMT, GTLB, CYBN, MNDY, ORCL.
What date range does this track record cover?
Sep 07, 2025 to Mar 15, 2026.
Share Card
